A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Sorafenib (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RESILIENCE
- Sponsors Bayer
- 25 Nov 2017 This trial has been completed in Germany (30 Oct 2017).
- 14 Nov 2017 Status changed from active, no longer recruiting to completed.
- 09 Jul 2017 Planned End Date changed from 30 Jun 2017 to 30 Sep 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History